Gastroduodenal “Dysbiosis”: a New Clinical Entity
Purpose of review
Like the rest of the gastrointestinal tract, the small intestine is colonised by microbes, but how this “microbiome” affects the immune system and digestive functions has largely been overlooked, especially in the “omics” era. Here, we present recent findings that show that the diversity, density and interactions of these microbes in the small intestine can play an important role in the pathogenesis of a number of gastrointestinal and extraintestinal disorders.
Changes in the small intestinal mucosa-associated microbiota (SI-MAM) have been shown to occur with inflammatory bowel diseases, functional gastrointestinal disorders, metabolic disorders such as obesity and type 2 diabetes. More recently, there is emerging evidence that small intestinal dysbiosis can be a driver for the progression of chronic liver disease. Initially believed that small intestinal dysbiosis (e.g. SIBO) is mainly due to alterations of luminal conditions (e.g. after surgical resections of the ileocecal valve), there is now enough evidence to conclude that small intestinal dysbiosis can occur without underlying structural abnormalities.
Alterations of the SI-MAM appear to play a key role for the manifestation and progression of inflammatory and metabolic disorders.
KeywordsMicrobiome Microbiota Small intestine
Compliance with ethical standards
Conflict of interest
Mark Morrison reports grants from the National Health and Medical Research Council, during the conduct of the study and personal fees from Janssen-Cilag Australia and Yakult Inc., outside the submitted work. Ayesha Shah and Gerald Holtmann declare no conflict of interest.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–79.Google Scholar
- 8.Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26.Google Scholar
- 26.• Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–9 Utilsing culture methods, SIBO was found in 37.5% of IBS sufferers (60% of IBS patients with predominant diarrhea compared to 27.3% without diarrhea).PubMedGoogle Scholar
- 28.Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin N Am. 2010;24:943–59 viii-ix.Google Scholar
- 32.Tillman R, King C, Toskes P. Continued Experience With The Xylose Breath Test-Evidence That The Small Bowel Culture As The Gold Standard For Bacterial Overgrowth May Be Tarnished, In Gastroenterology, Wb Saunders Co-Elsevier Inc 1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, Pa 19103–2899 Usa, 1981.Google Scholar
- 37.Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hörnquist E, de Vos WM, et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther. 2015;41:342–51.PubMedGoogle Scholar
- 38.Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–14.Google Scholar
- 42.Li G, Yang M, Zhou K, et al. Diversity of duodenal and rectal microbiota in biopsy tissues and luminal contents in healthy volunteers. J Microbiol Biotechnol. 2015.Google Scholar
- 49.•• Shanahan ER, Zhong L, Talley NJ, Morrison M, Holtmann G. Characterisation of the gastrointestinal mucosa-associated microbiota: a novel technique to prevent cross-contamination during endoscopic procedures. Aliment Pharmacol Ther. 2016;43:1186–96 A novel technique utilsing a sheeted biopsy forceps is used to assess the mucosa associated microbiome in the small intestine that overcomes problems of cross contamination when biospies taken during routine endoscopies.PubMedGoogle Scholar
- 57.American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1461–3.Google Scholar
- 63.•• Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32 Landmark study that demonstrated that in patients with non-constipated IBS treatment with a non-absorbable antibiotic resulted in a proportion of patients in a prolonged improvement of symptoms.PubMedGoogle Scholar
- 73.Zhao J, Zheng X, Chu H, Zhao J, Cong Y, Fried M, et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil. 2014;26:794–802.PubMedGoogle Scholar
- 75.Parodi A, Greco A, Savarino E, et al. May breath test be useful in diagnosis of IBS patients? An Italian study, in gastroenterology, WB SAUNDERS CO-ELSEVIER INC 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103–2899 USA, 2007.Google Scholar
- 88.•• Rana SV, Sharma S, Kaur J, Prasad KK, Sinha SK, Kochhar R, et al. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients. J Crohn's Colitis. 2014;8:859–65 UC patients with elevated inflammatory cytokines showed delayed gastrointestinal transit times and increased risk for SIBO.Google Scholar
- 89.•• Sánchez-Montes C, Ortiz V, Bastida G, et al. Small intestinal bacterial overgrowth in inactive Crohn’s disease: influence of thiopurine and biological treatment. World J Gastroenterol. 2014;20:13999–4003 Treatment with imunosuppressants is not associated with an increased SIBO risk in patients with Crohn's disease.PubMedPubMedCentralGoogle Scholar
- 90.Rutgeerts P, Ghoos Y, Vantrappen G, et al. Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease. Eur J Clin Investig. 1981;11:199–206.Google Scholar
- 92.Ricci JERJ, Chebli LA, Ribeiro T, et al. Small-intestinal bacterial overgrowth is associated with concurrent intestinal inflammation but not with systemic inflammation in Crohn's disease patients. J Clin Gastroenterol. 2018;52:530–6.Google Scholar
- 101.von Wulffen M, Clark PJ, Macdonald GA, Raj AS, Kendall BJ, Powell EE, et al. Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. Aliment Pharmacol Ther. 2016;44:68–77.Google Scholar
- 102.•• Shah A, Shanahan E, Macdonald GA, Fletcher L, Ghasemi P, Morrison M, et al. Systematic review and meta-analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis. 2017;37:388–400 This systematic review and metaanalysis provides strong evidence that SIBO is strongly associated with the progression of chronic liver disease.PubMedGoogle Scholar
- 103.Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731–6.PubMedPubMedCentralGoogle Scholar